Small molecule · Inhibitor of fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3) · developed by Hutchmed
Fanregratinib (HMPL-453) is an orally bioavailable small molecule that binds and inhibits fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3, blocking FGFR-related signal transduction and proliferation in FGFR-overexpressing tumor cells. It is being studied in advanced intrahepatic cholangiocarcinoma and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04353375 | Phase 2/3 | Advanced Intrahepatic Cholangiocarcinoma | Recruiting | HCM |
| NCT07697157 | Phase 1 | Health, Subjective | Completed | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Intrahepatic CholangiocarcinomaSolid Tumor, AdultHealth, Subjective
Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →